BlackRock’s Kyntra Bio KYNB Stock Holding History

BlackRock’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-120	Closed	-$8.1K	–	5476
2023 Q2	$8.1K	Buy	+120	New	+$49.6K	﹤0.01%	5272

Other funds holding KYNB

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

BlackRock's KYNB Position: Q1 2026 in Review

BlackRock reduced its Kyntra Bio (KYNB) stake by 0.42% in Q1 2026, selling an estimated $2.81K and leaving 84,331 shares worth $572K. The position accounts for ﹤0.01% of the portfolio, ranked #4491.

BlackRock first reported a position in KYNB in Q4 2014 and has held it in 46 quarters since. The position peaked at $387M in Q2 2018. 32 funds tracked by Wall St. Rank hold KYNB as of Q1 2026.

BlackRock held 84,331 shares of Kyntra Bio worth $572K as of Q1 2026.
BlackRock sold 359 Kyntra Bio shares in Q1 2026, an estimated $2.81K.
Kyntra Bio made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4491 holding.
BlackRock first reported a position in Kyntra Bio in Q4 2014 and has held it in 46 quarters since.
BlackRock's Kyntra Bio position peaked at $387M in Q2 2018.
32 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.